Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

LIVERAIM A Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy

Coordinator
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Spain
Runs
1 March 2024 to 28 February 2030
Status
Running
EU funding
€13.9m
Total cost
€25.2m
Partners
33 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101132901

What the project is doing

In the project's own words, from its summary on CORDIS.

Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems, causing 300K deaths per year in Europe. Predominant etiological factors are obesity, type2 diabetes, and increased alcohol in-take, which are all on the rise. It is predicted that healthy life expectancy will decrease in Europe over the next 30 years because of deaths due to liver disease.

Liver cirrhosis develops after a very long period of asymptomatic liver fibrosis, staying undetected until patients develop severe complications due to cirrhosis or liver cancer. Currently the only effective treatment available is liver transplantation which is not applicable to all patients. If fibrosis is detected early, to target the course of liver disease, then liver fibrosis is reversible. The LIVERAIM project concentrates a team of renowned clinical centres and Industrial partners, including SMEs, with great expertise in the field of Liver Disease, the aim being to design and validate a screening platform with biomarkers for population screening to use across Europe.

The objective is to identify liver disease early and apply personalized therapeutic interventions. A large number of existing biomarkers will be tested for fibrosis prediction accuracy using biobank plasma samples from 40,000 subjects from previous H2020 EU-funded cohorts. LIVERAIM will develop a screening platform with biomarkers using AI for personalized early diagnosis of fibrosis to be validated in a RCT of 100K subjects from 6 representative EU countries.

The platform will be linked to tailored, personalized therapeutic interventions to halt fibrosis progression. With LIVERAIM, early diagnosis and personalized intervention can stop liver disease progression, help decrease morbidity and mortality and the associated societal burdens both economic and health inequity.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainCoordinator
European Liver Patients AssociationBruxelles / BrusselBelgiumParticipant
European Association for the Studyof the LiverGeneveSwitzerlandAssociatedpartner
Roche Diagnostics International AGRotkreuzSwitzerlandParticipant
Universitat ZurichZurichSwitzerlandAssociatedpartner
Boehringer Ingelheim InternationalgmbhIngelheimGermanyParticipant
Siemens Healthcare GmbHErlangenGermanyParticipant
Siemens Healthineers AGForchheimGermanyParticipant
Sysmex Europe SeNorderstedtGermanyParticipant
Universitaetsmedizin Der Johannes Gutenberg-Universitaet MainzMainzGermanyParticipant
Universitat Des SaarlandesSaarbruckenGermanyParticipant
Nordic Bioscience A/sHerlevDenmarkParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Region SyddanmarkVejleDenmarkParticipant
Barcelona Supercomputing Center Centro Nacional De SupercomputacionBarcelonaSpainParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainParticipant
Universitat De BarcelonaBarcelonaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceThird party
EchosensParisFranceParticipant
Fondation Cardiometabolisme NutritionParisFranceParticipant
Klinicka Bolnica DubravaZagrebCroatiaThird party
Sveuciliste U Zagrebu Medicinski FakultetZagrebCroatiaParticipant
Gilead Sciences Ireland UcCarrigtoohillIrelandParticipant
Azienda Ospedale Universita PadovaPadovaItalyThird party
Innovation Acta SRLSienaItalyParticipant
Universita Degli Studi Di PadovaPadovaItalyParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Fakultna Nemocnica S Poliklinikou F.d. Roosevelta Banska BystricaBanska BystricaSlovakiaParticipant
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
Mayo ClinicRochesterUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI